FMC — FMC Corporation

FMC Corporation Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• GAAP Net Sales: $542 million, a 49% decline year-over-year, primarily due to significant one-time actions in India.
• Revenue Excluding India: $961 million, down 4% year-over-year, driven by a 6% price decline but a 2% increase in volume.
• Adjusted EBITDA: $236 million, with a margin of approximately 25%, reflecting a 17% increase year-over-year.
• Adjusted EPS: $0.89, up 30% from the prior year.
• Free Cash Flow: Negative $233 million for Q3, with a full-year guidance now adjusted to negative $200 million to $0.
• Net Debt: Approximately $4.0 billion, with a gross debt to trailing 12-month EBITDA ratio of 5x.

2. Strategic Updates and Business Highlights

• FMC is focusing on becoming a pure-play agricultural sciences company, with a strong pipeline of innovative technologies.
• Actions taken to address inventory issues in India included product returns and pricing credits to distributors.
• The company is initiating a strategic review of its manufacturing footprint to enhance cost competitiveness, particularly for non-IP protected products.
• FMC is investing in additional routes to market in Brazil, targeting large soybean and corn growers, with positive early results.

3. Forward Guidance and Outlook

• Q4 Sales Guidance: Expected to be between $1.12 billion and $1.22 billion, representing a 2% increase at the midpoint on a like-for-like basis.
• Q4 Adjusted EBITDA Guidance: Projected between $265 million and $305 million, a decline of 16% at the midpoint.
• Full-Year Revenue Guidance: Now expected to be between $3.92 billion and $4.02 billion.
• Adjusted EPS Guidance: Forecasted to be $2.92 to $3.14 for the full year.

4. Bad News, Challenges, or Points of Concern

• Sales were below expectations, particularly in Latin America, due to constrained credit and increased competition from generics.
• The company is facing pricing pressure, especially in Latin America, where generics are gaining market share due to favorable registration conditions.
• Free cash flow guidance has been significantly reduced due to lower cash from operations and collection delays, particularly in Latin America.
• The company reported a GAAP net loss of $569 million, largely due to charges related to the India business held for sale.
• Concerns about maintaining investment-grade ratings were raised, with discussions ongoing regarding financial covenants.

5. Notable Q&A Insights

• Management acknowledged that the primary driver for reduced cash flow guidance was collection delays, exacerbated by liquidity constraints in Latin America.
• The sale price for the India business is estimated at $450 million, with strong interest from both local and international buyers.
• Management remains committed to maintaining investment-grade ratings but recognizes current metrics are not aligned; they are focused on cash management and debt reduction.
• There is speculation on potential partnerships for new active ingredients, but selling any close-to-commercialization products is currently not on the table.
• The company is reassessing its manufacturing costs and may adjust pricing strategies in response to competitive pressures, particularly concerning Rynaxypyr.

Overall, FMC is navigating a challenging market environment while implementing strategic initiatives to enhance competitiveness and manage costs effectively.